2009 Volume 109 Issue 1 Pages 119-127
The hepatoprotective effects of ACTIValoe®N-931 complex, a mixture of Aloe vera and Silybum marianum, against acute and chronic carbon tetrachloride (CCl4)-induced liver injuries were investigated. Acute hepatotoxicity was induced by intraperitoneal injection of CCl4 (50 μl/kg), and ACTIValoe®N-931 complex at 85, 170, and 340 mg/kg was administered orally 48, 24, and 2 h before and 6 h after injection of CCl4. Hepatotoxicity was assessed 24 h after CCl4 treatment. Liver fibrosis was induced by intraperitoneal injection of CCl4 for 8 weeks (0.5 ml/kg, twice per week), and mice were treated with ACTIValoe®N-931 complex at 85, 170, or 340 mg/kg once a day (p.o.). In both acute hepatotoxicity and liver fibrosis, serum aminotransferase levels and lipid peroxidation were increased and the hepatic glutathione content was decreased. These changes were prevented by ACTIValoe®N-931 complex. The ACTIValoe®N-931 complex attenuated the increase in tumor necrosis factor-α (TNF-α), and inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2), mRNA expressions in acute hepatotoxicity. In antifibrotic experiments, tissue inhibitor of metalloprotease-1 (TIMP-1) mRNA expression was attenuated by treatment with ACTIValoe®N-931 complex. The ACTIValoe®N-931 complex decreased the hepatic hydroxyproline content and the transforming growth factor-beta1 levels. Our results suggest that the ACTIValoe®N-931 complex has hepatoprotective effects in both acute and chronic liver injuries induced by CCl4.